To determine whether inhibition of USP10 enhances the efficacy of IM, we examined the effect of Spautin-1 or various concentrations of IM alone or in combination on the cell viability of CML cells and primary monocytes from patients. The gene discussed is USP10; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.